Search

A patent application titled "Folded Pump-Outlet Tube" was published online by inventors from Israel, detailing a left-ventricular assist device design. The device includes a pump-outlet tube with blood-outlet openings, an impeller for blood pumping, and an expandable element to center the device within the aorta. The patent application focuses on the technical specifications and configurations of the device for assisting patients with failing hearts or undergoing cardiac procedures. [Extracted from the article]

Research from Houston Methodist Hospital explores the impact of statins on gastrointestinal bleeding events among patients with continuous-flow left ventricular assist devices (CF-LVADs). The study found that there was no significant difference in the incidence of major gastrointestinal bleeding events associated with statin therapy in CF-LVAD patients. Further research is needed to determine if a true association exists between statin use and gastrointestinal bleeding in this patient population. The study highlights the importance of considering factors such as age and baseline creatinine levels in assessing the risk of gastrointestinal bleeding post-CF-LVAD implantation. [Extracted from the article]

Researchers from Primary Children's Medical Center conducted a study on patient and parent-reported outcomes in pediatric ventricular assist device support. The study, part of the Advanced Cardiac Therapies Improving Outcomes Network, involved six centers and focused on improving clinical outcomes and patient experiences. Initial findings showed positive feedback from clinicians and participants, with common symptoms including limitations in activities, dressing change distress, and post-operative pain. The study demonstrated success in implementing a patient-reported outcomes program and highlighted the importance of further research and intervention in this area. [Extracted from the article]

The article discusses a clinical trial, NCT06655376, focusing on advanced heart failure patients supported by a Left Ventricular Assist Device (LVAD). The trial compares two antithrombotic regimens, one with aspirin and vitamin K antagonist (VKA) and the other without aspirin. The study aims to evaluate the safety and efficacy of the regimen without antiplatelet therapy, with a focus on reducing bleeding events. The trial is ongoing, with a primary completion date set for April 1, 2027. [Extracted from the article]

Researchers at Alvaro Cunqueiro Hospital in Vigo, Spain, have conducted a study on the use of intraoperative prophylactic right ventricular assist devices to prevent postcardiotomy failure in patients at risk of developing right ventricular failure after cardiac surgery. The study involved implanting four devices in patients with valvular heart disease and high risk of postoperative right ventricular failure, resulting in improved outcomes without any hospital mortality. The research suggests that prophylactic strategies like this may help decrease the incidence of refractory postoperative right ventricular failure. [Extracted from the article]

A patent application for an "Autologous Left Ventricle Assist Device" has been published online, detailing a device that aims to assist in pumping oxygenated blood efficiently without the need for external power sources. The device, which utilizes a patient's own tissues, such as the Latissimus Dorsi muscle, is designed to integrate with the body over several weeks and pump blood through the aorta with enhanced pressure. The application outlines a method for implanting and transforming the device into an autologous pumping device, providing potential benefits for patients with congestive heart failure. [Extracted from the article]

A patent application titled "Device And Method To Improve Cardiac Contractility And Enable Cardiac Recovery In Patients With Heart Failure" was published online by inventors from Tamil Nadu, India. The invention aims to address heart failure by improving cardiac muscle contractility and facilitating regeneration through long-term augmentation of coronary perfusion pressure. The device includes an electrically operated pump, a coronary infusion channel for delivering medications and stem cells, and a central processing unit for monitoring and controlling pump speed. This innovative approach focuses on improving coronary perfusion and cardiac output while minimizing the need for external power sources, offering potential benefits for patients with heart failure. [Extracted from the article]

A recent study conducted at Cincinnati Children's Hospital Medical Center focused on pediatric patients supported with ventricular assist devices (VADs) to predict the incidence of stroke. The study analyzed data from 1219 patients aged under 19 who received VADs between 2012 and 2022. The findings indicated a decrease in overall stroke rates, with specific improvements observed in paracorporeal pulsatile devices. The research highlighted risk factors for stroke and suggested insights for identifying higher-risk subsets and refining management strategies. [Extracted from the article]

A recent study conducted at Tufts Medical Center in Boston, Massachusetts, explored the association between pulmonary vascular resistance (PVR) and posttransplant outcomes in patients with and without left ventricular assist device (LVAD) support before heart transplantation (HT). The researchers analyzed data from adult first-time HT recipients and found that higher PVR was independently associated with a higher risk of early graft failure and 1-year mortality among LVAD patients. However, for patients surviving at least 1 year, PVR was not associated with long-term mortality in either subgroup. The study suggests that further research is needed to determine if more aggressive reduction of PVR in LVAD patients can mitigate these risks. [Extracted from the article]

A recent study conducted by researchers at Osaka University Graduate School of Medicine examined the occurrence of bleeding complications in patients with implantable left ventricular assist devices (LVAD). The study found that bleeding complications were a major cause of morbidity and mortality in these patients. The researchers discovered that hemodynamics after LVAD implantation and preoperative brachial-ankle pulse wave velocity (baPWV) were associated with bleeding complications. Additionally, high systemic vascular resistance (SVR) in the hemodynamic ramp test was linked to bleeding complications. The study concluded that arteriosclerosis is a risk factor for bleeding complications after LVAD implantation. [Extracted from the article]

A recent study conducted by researchers at the Medical Faculty and University Hospital Duesseldorf examined the involvement of specialist palliative care in patients with left ventricular assist devices (LVADs). The study found that specialist palliative care was available in 67.3% of LVAD centers, with a median duration of 17 months between LVAD implantation and first specialist palliative care contact. The study also revealed a high physical and psychosocial symptom burden in these patients, highlighting the need for earlier integration of palliative care to address poorly controlled symptoms. Further research and educational efforts are necessary to bridge the gap between guideline recommendations and current practices. [Extracted from the article]

A recent study conducted by the Division of Cardiology in Boston, Massachusetts, has focused on adverse events experienced by individuals with congenital heart disease (CHD) who are using ventricular assist devices (VADs). The study aimed to establish standardized definitions of pediatric and CHD adverse events for use in clinical trials, registries, and regulatory evaluations. Through a collaborative effort involving various stakeholders, including trialists, clinicians, patients, families, statisticians, biomedical engineers, device developers, and regulatory agencies, the study identified and defined 19 adverse event types related to VAD use in CHD patients. The findings of this study will facilitate the assimilation of data across future clinical trials and the evaluation of VADs for children and adults with CHD. [Extracted from the article]

A study conducted in Berlin compared the outcomes of patients with coronary artery disease (CAD) and advanced heart failure who underwent either coronary artery bypass grafting (CABG) or left ventricular assist device (LVAD) implantation. The study found that patients who underwent CABG had better mid-term survival rates compared to those who received LVAD implantation. However, LVAD patients had a lower incidence of postoperative renal replacement therapy and temporary mechanical circulatory support. The study suggests that CABG may be a preferable option for patients with CAD and advanced heart failure. [Extracted from the article]

A patent has been issued for a ventricular assist device developed by Magenta Medical Ltd. The device is designed to assist cardiac circulation in patients with a failing heart. It includes an impeller with a helical elongate element, a spring, and a film of material. The device also features an elongate tube with a self-expandable shape-memory alloy frame and a blood impermeable material. The impeller pumps blood from the left ventricle to the aorta and prevents backflow. The patent includes various claims related to the design and configuration of the device. [Extracted from the article]

A recent study conducted by researchers from the Indian Institute of Technology (IIT) Kharagpur focused on the development of a centrifugal flow left ventricular assist device (LVAD) through hydrodynamic simulation and experimentation. LVADs are considered the best alternative treatment for heart failure when organ donors are scarce, but they have been associated with complications such as thrombosis and hemolysis. The researchers aimed to address these concerns by designing a pump using computational fluid dynamics (CFD) and experimental evaluation. The results showed that the developed pump was capable of delivering blood at the required pressure without causing damage. This research was funded by the Ministry of Education and the Indian Council of Medical Research. [Extracted from the article]

A study conducted at the University of Rochester in New York examined the reliability of noninvasive blood pressure monitoring in patients with left ventricular assist devices (LVAD) during noncardiac surgeries. The researchers found that monitoring gaps of 10 minutes or longer were more common in patients with the HeartMate 2 LVAD compared to those with the HeartMate 3 LVAD. Morbid obesity and longer surgical duration were also associated with increased monitoring gaps. The findings suggest that anesthesiologists should consider the appropriateness of noninvasive blood pressure monitoring in LVAD patients undergoing noncardiac surgeries. [Extracted from the article]

A recent study conducted at the Hospital Clinic of Barcelona examined the use of anesthesia for non-cardiac procedures in patients with a left ventricular assist device (LVAD). The study found that standard anesthesia practices were generally suitable for these patients, with no intraoperative complications reported. The majority of procedures took place in the endoscopy unit, with gastrointestinal endoscopy being the most common procedure. Postoperative complications, such as lower gastrointestinal bleeding, were recorded in some cases. The study suggests that adherence to standard anesthesia practices can be effective for non-cardiac procedures in LVAD patients. [Extracted from the article]

A recent study from the University of Toronto highlights the challenges and outcomes of using left ventricular assist devices (LVADs) in pediatric patients with end-stage heart failure. The study found that there are limited LVAD options for children of different body sizes, with smaller patients experiencing higher rates of VAD-related stroke. However, the use of the HeartMate 3 (HM3) device has expanded to smaller patients, although they may be at a higher risk of infections, renal dysfunction, bleeding, and stroke. The study emphasizes the need for size-stratified analyses and device development to better serve the pediatric population. [Extracted from the article]

A report from the University of Alberta in Canada discusses the risk factors for thromboembolic events in pediatric patients with ventricular assist devices (VADs). The study found that pediatric patients on VADs are at risk of thromboembolic complications, and the researchers aimed to identify factors associated with these events. The study found that the initial anticoagulation strategy and device type were significant factors. The use of bivalirudin as the initial anticoagulation strategy was associated with a reduced hazard of thromboembolic events, while the use of paracorporeal continuous (PC) devices was associated with an increased hazard. Further research is needed to understand the interaction between device type and anticoagulation strategy. [Extracted from the article]

A systematic review conducted by researchers at the Mayo Clinic in Jacksonville, Florida, examined the outcomes of non-cardiac surgery in patients with left ventricular assist devices (LVADs). The review included 20 articles with a total of 6,476 LVAD patients who underwent 6,824 non-cardiac surgeries. The study found that non-cardiac surgery can be performed safely and effectively in LVAD patients, although perioperative management should be optimized to reduce mortality. Common complications included gastrointestinal bleeding, intracranial bleeding, infection, acute kidney injury, urinary tract infection, stroke, sepsis, pneumonia, and the need for LVAD exchange. The study did not conduct a meta-analysis due to the diverse range of patients and outcomes in each publication. [Extracted from the article]

A recent study conducted at the University of Alabama Birmingham explored the use of fusion imaging technology in guiding the placement of a percutaneous right ventricular assist device (RVAD) in a patient with post-operative right ventricular failure. Fusion imaging combines live transesophageal echocardiogram and real-time fluoroscopy to provide accurate guidance during the implantation procedure. The researchers concluded that fusion imaging technology can be a safe and effective tool for placing RVADs in patients with complex cardiac anatomy. This research has been peer-reviewed and published in the journal Echocardiography. [Extracted from the article]

A study conducted at the University of Texas Austin has explored the use of percutaneous ventricular assist devices (pVADs) with admittance electrodes for accurate volumetric measurements. The researchers aimed to validate the use of three electrodes instead of the standard four to reduce the size of the pVAD profile and minimize vascular complications. The study involved simulations and measurements using 3D-printed models of healthy and dilated hearts, and a modified equation was developed to improve the accuracy of calculated volumes. The findings suggest that reducing the electrode footprint can simplify the incorporation of admittance technology on pVADs, allowing for better monitoring of heart recovery and assistance with weaning from the device. [Extracted from the article]

A recent study conducted at the University Medical Center Utrecht in the Netherlands examined the outcomes of patients who underwent left ventricular assist device (LVAD) exchange. The study found that while the mortality rate for LVAD exchange was relatively low, other post-operative complications were common. Patients who had the HeartWare Ventricular Assist Device (HVAD) as their initial device were at a higher risk of developing right heart failure and respiratory failure after the exchange. The study highlights the need for further research and improved strategies to minimize complications associated with LVAD exchange. [Extracted from the article]

A recent report from the University of Rostock in Germany discusses the use of computational fluid dynamics (CFD) simulations to study ventricular assist devices (VADs) and their interaction with the cardiovascular system. The researchers aimed to validate critical simulation parameters for accurate VAD simulations and found that mesh size and time step sizes had the greatest influence on the calculated pump performance. The study contributes to advancing VAD simulations, which can ultimately enhance clinical efficacy and patient outcomes. For more information, the full article can be accessed through the provided link. [Extracted from the article]

A recent study conducted by the University of Maryland School of Medicine highlights the risks associated with left ventricular assist devices (LVADs) used in patients with end-stage heart disease. While advancements in LVAD technologies have improved patient outcomes, there are still significant risks involved. The study focuses on a laparoscopic technique for driveline tunneling during LVAD implantation, which can reduce the risk of intraabdominal injury. The researchers emphasize the importance of careful management during the procedure to prevent complications. This research provides valuable insights for healthcare professionals and patients considering LVAD implantation. [Extracted from the article]

A patent application titled "Methods For Treating Pulmonary Hypertension In Patients With Left Ventricular Assist Device Implantation" has been published online. The inventors propose methods for treating pulmonary hypertension in patients with left ventricular assist device (LVAD) implantation by administering therapeutically effective amounts of macitentan or aprocitentan. These methods aim to manage pulmonary hypertension in patients with LVAD implantation, which can lead to right ventricular failure and other complications. The patent application provides detailed information on the dosage and administration of these drugs for treating pulmonary hypertension and improving cardiac transplant eligibility in LVAD patients. [Extracted from the article]

A patent has been issued for a heart assist device developed by Star Bp Inc. The device aims to provide circulatory assistance for patients with congestive heart failure, offering potential benefits for those who are not candidates for cardiac transplantation. The device is designed to be inserted using minimally invasive techniques, reducing the risks associated with traditional methods. The patent describes the device's components, including a rotor with impeller blades and magnets, a pump housing, and a motor housing. The device is intended to draw blood into a pumping chamber and facilitate its flow through the heart. [Extracted from the article]

A systematic review conducted by researchers at the University of Rochester examined the association between psychosocial factors and outcomes in patients undergoing left ventricular assist device (LVAD) implantation. The review analyzed 20 relevant articles and found that non-adherence, psychiatric disorder, and substance use were consistently associated with an increased risk of mortality, readmission, and adverse events. However, the studies varied in their definitions of psychosocial factors and selected outcomes, and there was heterogeneity in research methodology and study quality. The researchers concluded that there is a need for adequately powered studies with uniform definitions of psychosocial factors to clarify their relationships with outcomes after LVAD implantation. [Extracted from the article]

A patent application has been submitted for a "Delivery Tube With Braid" to the US Patent and Trademark Office. This invention is a left-ventricular assist device that includes an impeller and a delivery tube. The delivery tube is designed to pass through different parts of the aorta, with an outer layer that varies in flexural rigidity along its length. The device also includes a drive cable that rotates the impeller to pump blood from the left ventricle into the aorta. The patent application provides detailed information about the design and composition of the delivery tube. [Extracted from the article]

A patent application has been submitted for a ventricular assist device with an impeller-stabilizing spring. The device is designed to assist and unload cardiac chambers in patients with a failing heart or those at risk during coronary interventions. The motion-cushioning spring acts as a shock absorber, providing cushioning to the axial back-and-forth motion of the impeller. The device also includes a distal thrust bearing to prevent axial motion of the impeller in response to pressure variations. An elastomeric material can be coupled to the motion-cushioning spring to reduce the risk of thrombi and hemolysis. The patent application provides further details and claims for the apparatus. [Extracted from the article]

A recent report discusses research on early ventricular arrhythmias (EVAs) after left ventricular assist device (LVAD) implantation. The study found that EVAs are a common complication after LVAD implantation and are associated with an increased risk of 30-day mortality. Risk factors for EVAs include a history of end-stage renal disease, preoperative electrical storm, and previous implantable cardiac defibrillator therapy. The study suggests that further research is needed to better understand the incidence and prognostic implications of EVAs in patients with LVAD. [Extracted from the article]

A recent study conducted by the Medical University of Silesia examined the impact of long-term continuous-flow left ventricular assist device (LVAD) therapy on fibrin clot permeability in patients with end-stage heart failure. The researchers found that patients on LVAD therapy experienced a decrease in fibrin clot permeability over time. This decrease was associated with higher fibrinogen concentration and factor VIII activity. Additionally, patients without adverse events showed a trend towards normalization of fibrin clot permeability, suggesting a potential link between clot structure and thromboembolic and bleeding complications. [Extracted from the article]

A recent study conducted by researchers at Soochow University in Suzhou, China, has proposed a new adaptive proportional derivative (APD) control system for left ventricular assist devices (LVADs). The APD control system aims to address the issue of high power consumption caused by the unclear mechanism of liquid disturbance during the lifting-up of the magnetic bearing in LVADs. The researchers developed a mathematical model to describe the rotor's operation in liquid filling and analyzed the disturbance caused by the liquid. The experimental results showed that the APD control system improved dynamic performance, reduced power consumption, and resulted in a shorter rise time without overshoot of rotor displacement compared to traditional fixed configurations. [Extracted from the article]

A new report from the University of Pennsylvania discusses the challenges of managing aortic valve damage after the implantation of a left ventricular assist device (LVAD). The study reviewed the experiences of six patients who required intervention for aortic regurgitation after LVAD implantation. The interventions included open surgical procedures and percutaneous strategies, such as device placement and transcatheter aortic valve replacement. The results showed resolution of aortic regurgitation and improved hemodynamics in all patients, although there were some deaths. The researchers concluded that with a tailored risk-adjusted approach, acceptable results can be achieved in managing LVAD-induced aortic valve regurgitation. [Extracted from the article]

A recent study conducted at San Diego State University has found that the formation of a vortex in the aortic sinus is crucial for optimizing blood flow in patients with left ventricular assist devices (LVADs). The researchers used a mock circulatory loop combined with an LVAD to visualize vortex formation in an experimental model of the aortic root. They discovered that maintaining intermittent aortic valve opening is important for LVAD patients, as disruption of the vortex can lead to flow stagnation and thrombus formation. This study provides valuable insights into the dynamics of blood flow during LVAD support and highlights the need for further investigation in this area. [Extracted from the article]